Mifepristone-Misoprostol Combination Versus Misoprostol Alone for Termination of Pregnancy With Intrauterine Fetal Demise

Background The safety and efficacy of mifepristone and misoprostol for termination of pregnancies up to 24 weeks have been reported in the literature. However, their usage in induction of labor in cases of late intrauterine fetal demise (IUFD) is restricted to observational and non-randomized controlled comparative trials. Hence, the aim of this study was to evaluate the efficacy of the mifepristone-misoprostol combination regimen for termination of early and late IUFD in comparison to the misoprostol-only regimen. Method This randomized comparative study enrolled 70 women with IUFD at a tertiary care center. Participants were allocated by block randomization using sealed, opaque envelopes to receive oral mifepristone followed by vaginal misoprostol (Group A; n = 35) or vaginal misoprostol alone (Group B; n = 35). The primary outcome was the induction-to-delivery interval, measured from administration of the first drug in the allocated regimen until fetal expulsion or delivery. Secondary outcomes were the number of misoprostol doses and maternal adverse events. Result The median induction-to-delivery interval was 20.08 hours (interquartile range (IQR), 12.33-30.29) in Group A and 15.25 hours (IQR, 11.27-21.36) in Group B; the difference was not statistically significant (p = 0.096). The median number of misoprostol doses was significantly lower in Group A than in Group B (0 (IQR, 0-2) versus 3 (IQR, 2-4); p < 0.0001). Maternal adverse-event distributions did not differ significantly between the groups (p = 0.326). Conclusion Mifepristone pretreatment significantly reduced the subsequent misoprostol requirement. However, neither the induction-to-delivery interval nor maternal adverse-event distributions differed significantly between the groups. These findings support a misoprostol-sparing effect of mifepristone but do not establish that either regimen is faster, safer, or superior overall.

Authors

Publication Details

Journal
Cureus
Published
2026-11-21
DOI
https://doi.org/10.7759/cureus.120057
Primary Topic
Reproductive Health and Contraception
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mifepristone-Misoprostol Combination Versus Misoprostol Alone for Termination of Pregnancy With Intrauterine Fetal Demise

Anshul Tripathi, Bindu Bajaj, Vaishali Gautam, Mansvi Raghav et al.
Cureus
Reproductive Health and Contraception
article

Mifepristone-Misoprostol Combination Versus Misoprostol Alone for Termination of Pregnancy With Intrauterine Fetal Demise

Anshul Tripathi, Bindu Bajaj, Vaishali Gautam, Mansvi Raghav, Pooja Nirban, Hansika Anuragi, Puja Yadav, Harsha Gaikwad
article en

Abstract

Background The safety and efficacy of mifepristone and misoprostol for termination of pregnancies up to 24 weeks have been reported in the literature. However, their usage in induction of labor in cases of late intrauterine fetal demise (IUFD) is restricted to observational and non-randomized controlled comparative trials. Hence, the aim of this study was to evaluate the efficacy of the mifepristone-misoprostol combination regimen for termination of early and late IUFD in comparison to the misoprostol-only regimen. Method This randomized comparative study enrolled 70 women with IUFD at a tertiary care center. Participants were allocated by block randomization using sealed, opaque envelopes to receive oral mifepristone followed by vaginal misoprostol (Group A; n = 35) or vaginal misoprostol alone (Group B; n = 35). The primary outcome was the induction-to-delivery interval, measured from administration of the first drug in the allocated regimen until fetal expulsion or delivery. Secondary outcomes were the number of misoprostol doses and maternal adverse events. Result The median induction-to-delivery interval was 20.08 hours (interquartile range (IQR), 12.33-30.29) in Group A and 15.25 hours (IQR, 11.27-21.36) in Group B; the difference was not statistically significant (p = 0.096). The median number of misoprostol doses was significantly lower in Group A than in Group B (0 (IQR, 0-2) versus 3 (IQR, 2-4); p < 0.0001). Maternal adverse-event distributions did not differ significantly between the groups (p = 0.326). Conclusion Mifepristone pretreatment significantly reduced the subsequent misoprostol requirement. However, neither the induction-to-delivery interval nor maternal adverse-event distributions differed significantly between the groups. These findings support a misoprostol-sparing effect of mifepristone but do not establish that either regimen is faster, safer, or superior overall.

Cureus
Reproductive Health and Contraception
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon